

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 06/22/2006

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/608,054	06/27/2003	Michael L.F. Chan	TRA-007 7895	
3897 7:	7590 06/22/2006		EXAMINER	
SCHNECK &	: SCHNECK	MILLER, BENA B		
P.O. BOX 2-E				
SAN JOSE, C.	A 95109-0005		ART UNIT	PAPER NUMBER
•			3725	

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action							
Before	the Filing of an Appeal	Brief					

Application No.	Applicant(s)	
10/608,054	CHAN, MICHAEL L.F.	
Examiner	Art Unit	
Bena Miller	3725	

• • • • • • • • • • • • • • • • • • • •	- LAUMINIO	7					
	Bena Miller	3725 .					
The MAILING DATE of this communication appe	ears on the cover sheet with the c	correspondence add	Iress				
THE REPLY FILED 30 May 2006 FAILS TO PLACE THIS APP	LICATION IN CONDITION FOR AL	LOWANCE.					
this application, applicant must timely file one of the follor places the application in condition for allowance; (2) a No	The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:						
b) The period for reply expires on: (1) the mailing date of this A							
TWO MONTHS OF THE FINAL REJECTION. See MPEP 7	Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).						
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of exunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office late may reduce any earned patent term adjustment. See 37 CFR 1.704(b NOTICE OF APPEAL	shortened statutory period for reply orighter than three months after the mailing date.	of the fee. The appropriate in the final Off	riate extension fee ice action; or (2) as				
2. The Notice of Appeal was filed on A brief in complishing the Notice of Appeal (37 CFR 41.37(a)), or any external a Notice of Appeal has been filed, any reply must be filed.	ension thereof (37 CFR 41.37(e)), to	avoid dismissal of the	ns of the date of ne appeal. Since				
<u>AMENDMENTS</u>							
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below);							
(c) ☐ They are not deemed to place the application in be appeal; and/or			the issues for				
(d) ☐ They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)).		ected claims.					
4. The amendments are not in compliance with 37 CFR 1.1		mnliant Amendment	(PTOL-324)				
5. Applicant's reply has overcome the following rejection(s)		, in plicate 7 th to train one	(1.102.02.1).				
Newly proposed or amended claim(s) would be a non-allowable claim(s).		timely filed amendme	ent canceling the				
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed:		il be entered and an	explanation of				
Claim(s) allowed: Claim(s) objected to: Claim(s) rejected:	•						
Claim(s) withdrawn from consideration:		•					
AFFIDAVIT OR OTHER EVIDENCE							
 The affidavit or other evidence filed after a final action, be because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e). 							
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar 	overcome <u>all</u> rejections under appe ry and was not earlier presented. S	al and/or appellant fa see 37 CFR 41.33(d)(ils to provide a 1).				
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	on of the status of the claims after e	ntry is below or attac	hed.				
11. The request for reconsideration has been considered by See Continuation Sheet.	ut does NOT place the application i	n condition for allowa	nce because:				
12. Note the attached Information Disclosure Statement(s). 13. Other:	(PTO/SB/08 or PTO-1449) Paper N	bena V	1,00.				
		Bena Miller Primary Examiner	VI COCC				
		•					

Art Unit: 3725

Continuation of 11. does NOT place the application in condition for allowance because: in reference to Applicant's remarks that McIlhenney fails to teach an inner rectangular cross section with opposed top and bottom sections....said inner box having transparent wall through which said gift is visible", the Examiner disagrees. Figure 6 of McIlhenney teaches the claimed elements as mentioned above. As indicated in the previous Office Action, the Examiner considers the combination of 11 and 12 to meet the claimed inner box.

In reference to Applicant's Affidavit filed 11/28/05, the Applicant appear to further argue the concept of commercial success. In response the examiner points oùt that An applicant who is asseding commercial success to support its contention of nonobviousness bears the burden of proof of establishing a nexus between the claimed invention and evidence of commercial success. The Federal Circuit has acknowledged that applicant bears the burden of establishing nexus, stating: In the ex parte process of examining a patent application, however, the PTO lacks the means or resources to gather evidence which supports or refutes the applicant's assession that the sale constitute commercial success. C.f. Ex parte Remark! 15 USPQZd 1498, 1503 (Bd. Pat. App. & Int. Iggoltevidentiary routine of shlfting burdens in civil proceedings inappropriate in ex parte prosecution proceedings becâuse examiner has no available means for adducing evidence). Consequently, the PTO must rely upon the applicant to provide hard evidence of commercial success. In re Huang, 100 F.3d 135, 139-40, 40 USPQZd 1685, 1689 (Fed. Cir. 1996). See also In re GPAC, 57 F.3d 1573, 1580, 35 USPQZd 1 1 16, 1 121 (Fed. Cir. 1995)., In re Paulsen, 30 F.3d 1475, 1482, 31 USPQZd 1671, 1676 (Fed. Cir. 1994) (Evidence of commercial success of articles not covered by the claims subject to the 35 U.S.C. 103 rejection was not probative of nonobviousness). The term "nexus" designates a factually and legally sufficient connection between the evidence of commercial success and the claimed invention so that the evidence is of probative value in the determination of nonobviousness. Demaco Corp. v. F. Von Langsdoe Licensing Ltd., 851 F.2d 1387, 7 USPQZd 1222 (Fed. Cir. 1988)..

In considering evidence of commercial success, care should be taken to determine that the commercial success allegedê is directly derived from the invention claimed, in a marketplace where the consumer is free to choose on the basis of objective principles, and that such success is not the result of heavy promotion or advertising shift in advertising, consumption by purchasers normally tied to applicant or assignee, or other business events extraneous to the merits of the claimed invention, etc. In re Mageli, 470 F.2d 1380, 176 USPQ 305 (CCPA 1973) (conclusory statements or opinions that increased sales were due to the merits of the invention are entitled to little weightl; In re Noznick, 478 F.2d 1260, 178 USPQ 43 (CCPA 1973). In ex parte proceedings before the Patent and Trademark Office, an applicant must show that the claimed features were responsible for the commercial success of an article if the evidence of nonobviousness is to be accorded substantial weight. See In re Huang, 100 F.3d 135, 140, 40 USPQZd 1685, 1690 (Fed. Cir. 1996) (Inventor's opinion as to the purchaser's reason for buying the product is insufficient to demonstrate a nexus between the sales and the claimed invention.). Merely showing that there was commercial success of an adicle which embodied the invention is not sufficient. Ex parte Remark, 15 USPQZd 1498, 1502-02 (Bd. Pat. App. & Inter. 1990). Compare Demaco Corp. v. F. Von Langsdoe Licensing Ltd., 851 F.2d 1387, 7 USPQZd 1222 (Fed. Cir. 1988) (In civil litigation, a patentee does not have to prove that the commercial success is not due to other factors. "A requirement for proof of the negative of all imaginable contributing factors would be unfairly burdensome, and contrary to the ordinary rules of evidence.'). See also Pentec, Inc. v. Graphic Controls Corp., 776 F.2d 309, 227 USPQ 766 (Fed. Cir. 1985) (commercial success may have been attributable to extensive advertising and position as a market leader before the introduction of the patented productl; In re Fielder, 471 F.2d 690, 176 USPQ 300 (CCPA 1973) (success of invention could be due to recent changes in related technology or consumer demand', here success of claimed voting ballot could be due to the contemporary drive toward greater use of automated data processing techniques; EWP Corp. v. Reliance Universal, Inc., 755 F.2d 898, 225 USPQ 20 (Fed. Cir. 1985) (evidence of licensing is a secondary consideration which must be carefully appraised as to its evidentiary value because licensing programs may succeed for reasons unrelated to the unobviousness of the product or process, e.g., license is mutually beneficial or less expensive than defending infringement suits); Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 231 USPQ 81 (Fed. Cir. 1986) (Evidence of commercial success supported a conclusion of nonobviousness of claims to an immunometric "sandwich" assay with monoclonal antibodies. Patentee's essays became a market leader with 25% of the market within a few years. Evidence of advertising did not show absence of a nexus between commercial success aid the merits of the claimed invention because spending 25-35% of sales on marketing was not inordinate (mature companies spent 17-32% of sales in this market), and advertIsing served primarily to make industry aware of the product because this is not kind of merchandise that can be sold by advedising hyperbole.)

Although Applicant present an affidavit reflecting a positive public feedback, Applicant has not provided a nexus between their claimed product and its purported commercial success.